PolyPid Ltd. (NasdaqCM: PYPD)
Health Care · Pharmaceuticals · IL
$5.07
-2.31% today · +51.8% 1Y
PolyPid Ltd. (NasdaqCM: PYPD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $102.98M and employs 72 people.
Over the last twelve months the share price has gained 51.8%, trading between 3.06 and 5.73.
Tweenvest scores PolyPid Ltd. across four factors: quality 34/100, value 82/100. Its strongest factor is value.
PYPD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $102.98M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.48
- Dividend yield
- —
- Beta (5Y)
- 1.38
- 52-week high
- $5.73
- 52-week low
- $3.06
- Avg volume (3M)
- —
- Shares outstanding
- 20.31M
- Employees
- 72
- Next earnings
- —
About PolyPid Ltd.
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
- ISIN
- IL0011326795
- Founded
- 2008
- Listed since
- Jun 26, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd.TWSE: 1752 | $105.02M | NT$33.25 | +5.72% |
| Vita Life Sciences LimitedASX: VLS | $104.53M | AU$2.78 | -0.71% |
| Aardvark Therapeutics, Inc.NasdaqGS: AARD | $104.17M | $4.76 | +1.06% |
| Themis Medicare LimitedBSE: 530199 | $103.78M | Rs109.05 | -4.43% |
| Bafna Pharmaceuticals LimitedNSEI: BAFNAPH | $102.17M | Rs418.00 | +10.36% |
| October Pharma S.A.ECASE: OCPH | $101.60M | EGP221.69 | -1.00% |
| RaQualia Pharma Inc.TSE: 4579 | $100.94M | ¥614.00 | +0.82% |
| Intech Biopharm CorporationTPEX: 6461 | $100.75M | NT$29.20 | +10.40% |
Figures last refreshed Oct 11, 2026.